Didanosine (Videx)

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.

Also Known As:

Networked: 632 relevant articles (29 outcomes, 126 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Soriano, Vincent: 8 articles (05/2010 - 05/2003)
2.	Barreiro, Pablo: 7 articles (05/2010 - 05/2003)
3.	Ribera, Esteban: 5 articles (01/2009 - 01/2005)
4.	Lori, Franco: 5 articles (07/2005 - 01/2003)
5.	Haas, David W: 4 articles (01/2020 - 08/2006)
6.	Reiss, Peter: 4 articles (01/2016 - 09/2007)
7.	Maida, Ivana: 4 articles (05/2010 - 04/2006)
8.	Perronne, Christian: 4 articles (03/2008 - 12/2004)
9.	Lisziewicz, Julianna: 4 articles (07/2005 - 01/2003)
10.	Hulgan, Todd: 3 articles (01/2020 - 08/2006)

Related Diseases

1.	HIV Infections (HIV Infection) 12/01/1996 - "In conclusion, didanosine monotherapy is an effective treatment of HIV infection. " 02/01/1997 - "Italian multicentre study of didanosine compassionate use in advanced HIV infection. " 05/01/1995 - "Starting in 1988, 72 patients with advanced human immunodeficiency virus (HIV) infection were enrolled in a phase I study of didanosine at the National Cancer Institute. " 08/01/2004 - "A 63-year-old man with human immunodeficiency virus (HIV) infection tolerated several didanosine-containing antiretroviral regimens. " 01/01/2002 - "Didanosine is now used extensively as an integral component of multidrug combination regimens in both adults and children with HIV infection, and is now available for once-daily administration in the United States, Canada, and Europe. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 02/01/2003 - "This evaluation includes 394 subjects who participated in Pediatric AIDS Clinical Trials Group (PACTG) Study 152 and received either ZDV alone or in combination with didanosine. " 02/15/2002 - "The contribution of virologic and host factors to CD4 cell depletion associated with human immunodeficiency virus (HIV) type 1 was evaluated in children drawn from a larger efficacy trial of 2 doses of didanosine (ddI) monotherapy (Pediatric AIDS Clinical Trials Group 144). " 03/20/2000 - "Didanosine pharmacokinetics were determined during fasting and fed conditions in HIV-infected children enrolled in the Pediatric AIDS Clinical Trials Group Protocol 144 randomized to receive didanosine at 50 mg/m2 or 150 mg/m2 orally every 12 hr. Pharmacokinetic parameters from patients in the low (n = 39) and high (n = 38) dosing groups were not significantly different, but intersubject variability was substantial. " 11/01/1999 - "Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study." 04/01/1995 - "Among 34 children with AIDS enrolled in a trial with 2'-3' dideoxyinosine (ddI), six (aged 1-6 years) developed liver abnormalities within 2-18 months after institution of ddI. "
3.	Infections 05/01/1995 - "Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection." 08/01/2007 - "Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. " 05/01/2000 - "The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. " 07/01/1997 - "The role of didanosine in the management of HIV-1 infection." 06/01/1996 - "Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. "
4.	AIDS-Related Complex (ARC) 10/01/1993 - "These data suggest that didanosine was generally well tolerated in hemophiliacs with AIDS or ARC, and its administration correlated with improvement in constitutional symptoms and laboratory findings. " 10/01/1993 - "Phase I/II trial of didanosine (2',3'-dideoxyinosine) in hemophiliac patients with AIDS or AIDS-related complex." 02/01/1993 - "Long-term follow-up of 44 patients with AIDS or AIDS-related complex (ARC) in a phase 1 trial of didanosine is reported. " 01/01/1992 - "Neuropathic complaints were frequently observed in a Phase I study of dideoxyinosine (ddI) in 44 patients with AIDS and AIDS-related complex. " 07/01/1990 - "The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles."
5.	Disease Progression 07/01/2002 - "Anemia and cumulative toxicity with didanosine were the most important side effects of combination treatment, but it did not affect HIV disease progression. " 07/01/1992 - "However, the effects of didanosine on clinical end-points (disease progression, survival, HIV encephalopathy) remain to be established. " 06/12/1997 - "At the end of the study, didanosine alone had an efficacy similar to that of zidovudine plus didanosine (median follow-up, 32 months) (relative risk of disease progression or death, 0.98; 95 percent confidence interval, 0.70 to 1.37; P=0.91). " 12/05/2003 - "CXCR4-using virus was present from the onset (five patients) or appeared during clinical progression in all other patients, while taking zidovudine or didanosine monotherapy. " 01/01/2002 - "Didanosine was originally introduced as an alternative to zidovudine (ZDV) for patients who were intolerant of ZDV or experienced disease progression during ZDV monotherapy. "

Related Drugs and Biologics

1.	Zidovudine (Retrovir)
2.	Nevirapine (Viramune)
3.	Stavudine (Zerit)
4.	Zalcitabine (Hivid)
5.	efavirenz (Sustiva)
6.	Hydroxyurea (Hydrea)
7.	Antiviral Agents (Antivirals)
8.	Immunoglobulins (Immunoglobulin)
9.	Lamivudine (Epivir)
10.	Nucleosides

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Ligation
4.	Art Therapy
5.	Aftercare (After-Treatment)